

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRELIMINARY FINANCIAL INFORMATION OF KPC FOR THE YEAR ENDED 31 DECEMBER 2024

On 10 February 2025, KPC released its unaudited preliminary financial information for the year ended 31 December 2024.

KPC Pharmaceuticals, Inc (昆藥集團股份有限公司) (“**KPC**”) is a company incorporated in the People’s Republic of China. The shares of KPC are listed on the Shanghai Stock Exchange. As of the date of this announcement, KPC is owned as to approximately 28.05% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), through its non-wholly owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (華潤三九醫藥股份有限公司), and is a subsidiary of the Company.

On 10 February 2025, KPC released its unaudited preliminary financial information for the year ended 31 December 2024 (the “**Reporting Period**”) (the “**KPC Preliminary Financial Information**”). Set out below are the key financial information of the KPC Preliminary Financial Information:

I. MAJOR FINANCIAL INFORMATION AND INDICATORS FOR THE YEAR OF 2024 (UNAUDITED)

Unit: RMB ten thousand

Item	The Reporting Period	The corresponding period of previous year (after retrospective adjustment)	The corresponding period of previous year (before retrospective adjustment)	Increase/ (decrease) (after retrospective adjustment) (%)	Increase (before retrospective adjustment) (%)
Total operating revenue	840,144.72	843,017.71	770,312.13	(0.34)	9.07
Operating profit	92,754.66	78,966.97	56,849.59	17.46	63.16
Total profit	93,457.02	78,637.65	56,361.99	18.85	65.82
Net profit attributable to the shareholders of the listed company	64,808.13	54,071.06	44,468.00	19.86	45.74
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	43,611.44	33,511.17	33,511.17	30.14	30.14
Basic earnings per share (RMB)	0.86	0.71	0.59	21.13	45.76
Weighted average return on net asset (%)	9.52	8.55	8.64	0.97 percentage point	0.88 percentage point

Item	As of the end of the Reporting Period	As of the beginning of the Reporting Period	As of the beginning of the Reporting Period (after retrospective adjustment)	Increase/ (decrease) before retrospective adjustment (%)	Increase/ (decrease) after retrospective adjustment (%)
Total assets	1,261,136.71	1,229,538.40	956,538.33	2.57%	31.84%
Equity attributable to the shareholders of the listed company	525,364.85	656,248.43	529,744.41	(19.94%)	(0.83%)
Share capital	75,697.58	75,798.70	75,798.70	(0.13%)	(0.13%)
Net assets per share attributable to the shareholders of the listed company (RMB)	6.94	8.66	6.99	(19.86%)	(0.72%)

Notes:

- (1) The above information is based on information from unaudited consolidated financial statements. The financial information set out in the 2024 annual report to be published by KPC shall prevail.
- (2) KPC acquired a 51% equity interest in Kunming China Resources Shenghuo Pharmaceutical Co., Ltd. (昆明華潤聖火藥業有限公司) (“CR Shenghuo”) in cash in 2024. This transaction is classified as a business combination under common control. KPC has adjusted and restated the financial data for the same period of the previous year.
- (3) After the restatement adjustment in 2023, the equity attributable to shareholders of the listed company has already included CR Shenghuo and the merger consideration was paid in 2024. Therefore, after the restatement adjustment, the equity attributable to shareholders of the listed company and the net asset per share attributable to shareholders of the listed company decreased year-on-year.
- (4) According to the “Explanatory Announcement No. 1 on Information Disclosure by Companies Publicly Issuing Securities — Non-recurring Profit and Loss (Revised 2023) (《公開發行證券的公司信息披露解釋性公告第1號 — 非經常性損益(2023年修訂)》)”, the net profit or loss generated by subsidiaries in mergers of enterprises under common control during the period from the beginning of the reporting period up to the date of merger is considered non-recurring profit and loss. The net profit of CR Shenghuo in 2023 and 2024 were therefore reflected as non-recurring profit and loss in the consolidated financial statements of KPC. Thus, the net profit attributable to shareholders of the listed company, excluding non-recurring profit and loss, remained unchanged before and after restatement.

II. DETAILS OF OPERATING RESULTS AND FINANCIAL POSITIONS

On 20 December 2024, KPC completed the acquisition of a 51% equity stake in CR Shenghuo and included it within the scope of its consolidated financial statements. According to the relevant provisions of the “Enterprise Accounting Standards,” KPC retrospectively adjusted the financial data for the same period of the previous year based on the principles of business combination under common control.

KPC has adhered to its corporate mission of “Great Medicine with Profound Virtue, and Caring for the People’s Health,” and set its right strategic direction and clear development path. KPC is committed to building itself into a “leader in the silver health industry, a leader in premium national medicine, and a leader in elderly health and chronic disease management” as its strategic goals. KPC, leveraging on its diverse product portfolio with competitive advantage, has been enhancing its position in the chronic disease management sector, especially in elderly health, along with its strengths in the Panax notoginseng series and the “Kun Zhong Yao 1381 (昆中藥1381)” and “777” brands. KPC will continue to expand its business scale, improve its financial performance, solidify its market position in the elderly health and chronic disease management field, steadily and orderly promote in-depth reforms in business and organizational aspects, fully activate endogenous power, deeply cultivate the silver health sector, and continuously enhance its core competitiveness.

In 2024, KPC vigorously promoted long-term, stable, high-quality development and achieved good operating results, with operating revenue reaching RMB8,401.4472 million, representing an increase of approximately of 9.07% compared to the previous year’s audited figures (before restatement adjustment) and a decrease of approximately 0.34% compared to that after the restatement adjustment. The net profit attributable to shareholders of the listed company was RMB648.0813 million, reflecting an increase of approximately 45.74% as compared to the previous year’s audited figures (before restatement adjustment) and an increase of approximately 19.86% as compared to that after the restatement adjustment. The net profit attributable to shareholders of the listed company, excluding non-recurring profit and loss, was RMB436.1144 million, representing an increase of approximately 30.14% as compared to the previous year’s audited figures (before restatement adjustment) and an increase of approximately 30.14% as compared to that after the restatement adjustment.

The KPC Preliminary Financial Information have been prepared in accordance with the PRC Generally Accepted Accounting Principles and are unaudited. The final audited results for the Reporting Period to be disclosed by KPC in its 2024 annual report shall prevail.

The financial information is limited to KPC only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the KPC audited annual financial results of KPC, please refer to the annual report for the year ended 31 December 2024 to be published by KPC on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By Order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 10 February 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.